Healthcare entity
Every one of those 2 sits in a single category, market-trends. Insilico Medicine is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Each story carries 2.5 original sources on average, compared with 6.5 for the broader beat in this window.
Last mentioned: Jun 23, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, market-trends. Insilico Medicine is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Each story carries 2.5 original sources on average, compared with 6.5 for the broader beat in this window. The 23-day window averages about 0.6 stories each week. Their average consequence score of 7.5 runs above the beat's 6.5 for that window. Pharma.AI appears in 2 tracked Healthcare stories published from June 23, 2026 through July 15, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 111 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Pharma.AI. Shared-story counts are live from our verified record — not editorial picks.
The strategic alliance between AI drug discovery firm Insilico Medicine and global CDMO Bora Pharmaceuticals seeks to merge generative AI with manufacturing at scale. With a potential value exceeding $2.5 billion, the partnership could accelerate drug development and strengthen supply chain resilience, directly impacting healthcare delivery and cost structures.
A breakthrough $2.5B collaboration between AI drug discoverer Insilico Medicine and CNS specialist SK Biopharmaceuticals aims to tackle devastating neuroimmune disorders that have long defied conventional drug development. By combining generative AI with established clinical expertise, the partnership could dramatically shorten timelines and deliver first‑in‑class therapies to patients with conditions like Alzheimer's, multiple sclerosis, and rare neuroinflammatory diseases.
Pharma.AI is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
